China Biotech AI Briefing: From Model Score to Lab Evidence
A practical briefing for biotech leaders evaluating an AI partner: specify the scientific decision, inspect the validation split, and agree a prospective experiment.
A useful China biotech AI briefing should end with an experiment your scientific team can evaluate. Start by identifying the decision the model changes: which candidate to synthesise, which assay to run next, or which result needs investigation. A performance chart becomes useful only when its dataset and evaluation design match that decision.
This guide proposes a partner-assessment exercise for visiting executives. It does not report a completed company visit or establish the clinical effectiveness of a product.
Choose the decision before choosing the host
Ask the research lead to complete this sentence before meetings are booked: “We would use this output to choose ___, instead of our current method ___.” A target-prioritisation team and a manufacturing-quality team may both request “biotech AI,” but they need different demonstrations and different evidence owners.
For discovery work, request a discussion with someone who can explain the experimental design and the unsuccessful candidates. For a quality-control use case, ask for the process owner who understands how an abnormal output is investigated. A general presentation cannot answer both teams' questions in the same depth.
The industry deep-dive program can be scoped around this decision and the people needed to examine it. Specific host access must be confirmed during program design.
Use this evidence table during the meeting
| Question | Material to request | What would remain unresolved |
|---|---|---|
| What was the model allowed to see? | Dataset provenance and dates, including excluded records | Whether your organisation can obtain comparable inputs |
| How were training and evaluation separated? | A split description appropriate to the scientific question | Whether related compounds or repeated measurements make the test too easy |
| What was compared with the model? | The existing selection method evaluated on the same task | Whether the improvement survives a fair comparison |
| Which suggestions failed in the lab? | A consented, redacted example and the subsequent investigation | Whether the failure is tolerable in your proposed use |
| Who owns the next experiment? | A named scientific owner, assay plan and result-review date | Whether the partner can execute beyond a demonstration |
These are proposed diligence questions, not a checklist proving that a system is fit for clinical or regulatory use. If records cannot be shared, ask whether a controlled review or an independently run test is possible. Record that gap rather than filling it with a vendor's headline metric.
An illustrative candidate-selection exercise
Suppose your team has resources for twelve assays. Ask the partner to propose a small evaluation comparing model-led selection with your existing selection method under the same assay budget. Before results are available, agree how candidates enter each group, what counts as a usable result and how failed or incomplete assays will be reported.
Keep the exercise prospective: document the selections before the lab results are known. Ask a scientist who did not produce the model ranking to review the result record. The purpose is to learn whether the proposed workflow helps your next research decision; twelve assays alone would not establish broad generalisability.
The number twelve is an illustrative planning constraint, not a recommended sample size. Your scientific team should determine an appropriate design for its endpoint, variability and research stage.
Keep the regulatory boundary explicit
The FDA's January 2025 draft guidance on AI supporting drug and biological-product regulatory decisions describes credibility assessment for a specified context of use. The page identifies it as draft, non-binding guidance, not for implementation. It is a US reference for framing questions; it does not establish Chinese approval requirements or validate a prospective partner.
For any proposed regulated use, the delegation's regulatory lead should identify the applicable jurisdiction and evidence requirements separately. Keep exploratory research claims distinct from claims about safety, effectiveness or regulatory acceptance.
Leave with a short experimental brief
Write down the decision, dataset permissions, comparison method, scientific owner, unresolved evidence and conditions for stopping. If a partner cannot support that brief yet, a second technical discussion may be more useful than a commercial commitment. Our program design method explains how a decision-led brief shapes the visit agenda.